Verastem Oncology
117 Kendrick Street
Suite 500
Needham
MA
02494
United States
Tel: (718) 292-4200
Website: http://www.verastem.com/
Email: info@verastem.com
About Verastem Oncology
Verastem Oncology (Nasdaq: VSTM) is a clinical-stage biopharmaceutical company committed to the development and commercialization of medicines to improve the lives of patients diagnosed with cancer. We are driven by the strength, tenacity and courage of those battling cancer – single-minded in our resolve to deliver new therapies that not only keep cancer at bay, but improve the lives of patients diagnosed with cancer. Because for us, it’s personal.
Our team is anchored by core values of character, urgency, respect and excellence. We pride ourselves in being an organization committed to diversity and inclusion in order to achieve and sustain excellence. At Verastem, we believe that empowering employees is what makes them truly care about the important work they do.
Founded: 2010
387 articles with Verastem Oncology
-
New Verastem Oncology Initiative, Let’s Talk About LGSOC, Calls Attention to Rare Form of Ovarian Cancer
3/15/2023
Verastem Oncology today announced the launch of Let’s Talk About LGSOC, a new initiative that calls attention to low-grade serous ovarian cancer (LGSOC).
-
Verastem Oncology Reports Fourth Quarter and Full Year 2022 Financial Results and Highlights Recent Company Progress
3/14/2023
Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today reported financial results for the three months and full year ended December 31, 2022, and highlighted recent progress.
-
Verastem Oncology Outlines Key 2023 Strategic Priorities and Upcoming Catalysts for Advancing Avutometinib as a Backbone of Therapy for RAS Pathway-Driven Cancers
2/2/2023
Verastem Oncology today outlined key strategic priorities and upcoming catalysts to support its lead compound RAF/MEK clamp avutometinib in RAS pathway-driven cancers.
-
Verastem Oncology Announces Up to $60 Million Private Placement Offering of Series B Convertible Preferred Stock
1/24/2023
Verastem Oncology (Nasdaq:VSTM) today announced that it has entered into a definitive agreement to sell approximately 2.1 million shares of its Series B Convertible Preferred Stock (the “Preferred Stock”) to affiliates of BVF Partners L.P. in a private placement to raise aggregate gross proceeds of up to approximately $60 million in two tranches, before deducting fees to the placement agent and other estimated offering expenses payable by the Company.
-
Verastem Oncology Announces Positive Data and Regulatory Update from Planned Interim Analysis of Registration-Directed Phase 2 RAMP-201 Trial of Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer
1/24/2023
Verastem Oncology (Nasdaq: VSTM) today announces positive interim data from Part A of the ongoing RAMP 201 (ENGOTov60/GOG3052) international registration-directed Phase 2 study evaluating the safety and efficacy of avutometinib (VS-6766) alone and in combination with defactinib among patients with recurrent low-grade serous ovarian cancer (LGSOC).
-
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Jan 18, 2023
1/18/2023
Verastem Oncology, a biopharmaceutical company committed to advancing new medicines for patients with cancer, announced the grant of 96,700 restricted stock units to four new employees.
-
Verastem Oncology Appoints Rob Gagnon to Board of Directors
12/15/2022
Verastem Oncology, a biopharmaceutical company committed to advancing new medicines for patients with cancer, announced the appointment of Robert Gagnon to its Board of Directors, effective December 13, 2022.
-
Verastem Oncology Reports Third Quarter 2022 Financial Results and Highlights Recent Company Progress
11/3/2022
Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today reported financial results for the three months ended September 30, 2022, and highlighted recent progress.
-
Verastem Oncology Appoints Anil Kapur to Board of Directors
10/20/2022
Verastem Oncology (Nasdaq:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced the appointment of Anil Kapur to its Board of Directors, effective October 20, 2022.
-
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - October 07, 2022
10/7/2022
Verastem Oncology, a biopharmaceutical company committed to advancing new medicines for patients with cancer, announced the grant of stock options to purchase 22,500 shares of its common stock and the grant of 15,000 restricted stock units to one new employee.
-
Verastem Oncology Announces RAMP VS-6766 Clinical Trials and Corporate Updates
10/4/2022
FDA Meeting Planned for Q4 to Discuss Regulatory Path Forward Based on Encouraging Results to Date in Ongoing RAMP 201 Trial in LGSOC.
-
In an 8-4 vote, the FDA’s Oncologic Drugs Advisory Committee Roster voted against the benefit-risk profile of Secura Bio’s P13K inhibitor Copiktra (duvelisib).
-
The FDA will meet Friday to discuss the future of Secura Bio’s Copiktra (duvelisib), which has been approved as a third-line treatment for relapsed or refractory CLL/SLL.
-
Verastem Oncology Reports Second Quarter 2022 Financial Results and Highlights Recent Company Progress
8/8/2022
Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today reported financial results for the three months ended June 30, 2022, and highlighted recent progress.
-
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - July 07, 2022
7/7/2022
Verastem Oncology, a biopharmaceutical company committed to advancing new medicines for patients with cancer, announced the grant of stock options to purchase 120,500 shares of its common stock and the grant of 80,400 restricted stock units to four new employees.
-
Verastem Oncology Provides Update on RAMP 201 Study Evaluating VS-6766 ± Defactinib in Low-Grade Serous Ovarian Cancer
6/6/2022
Interim Analysis Findings Support Continued Evaluation of Both Monotherapy and Combination Therapy.
-
Verastem Oncology Awarded Pancreatic Cancer Action Network’s First Therapeutic Accelerator Award to Evaluate the Combination of VS-6766 and Defactinib in Front-Line Metastatic Pancreatic Cancer
5/18/2022
Verastem Oncology today announced that it has received the first “Therapeutic Accelerator Award” from the Pancreatic Cancer Network (PanCAN).
-
Verastem Oncology Reports First Quarter 2022 Financial Results and Highlights Recent Company Progress
5/9/2022
Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today reported financial results for the three months ended March 31, 2022 and highlighted recent progress.
-
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Apr 04, 2022
4/4/2022
Verastem Oncology, a biopharmaceutical company committed to advancing new medicines for patients with cancer, announced the grant of stock options to purchase 435,750 shares of its common stock and the grant of 240,900 restricted stock units to nine new employees.
-
Verastem Oncology Reports Fourth Quarter and Full Year 2021 Financial Results and Highlights Recent Company Progress
3/28/2022
Verastem Oncology today reported financial results for the three months and full year ended December 31, 2021, and highlighted recent progress.